What's breaking now, across thousands of outlets.
The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
While tech oligarchs grandstand about the existential danger AI superintelligence poses to humanity, former Environmental Protection Agency officials say we should be worried about a more immediate…
Your browser does not support the audio element.
A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push pharmaceutical manufacturers to raise prices or delay launches.
The Pennsylvania Department of Health has reported 676 measles cases in the state.
Authorities said the 40-year-old woman, who was unvaccinated, died Saturday from complications associated with measles.
